To access this video please...

BConnect: What’s new in HR+/HER2- EBC – latest findings from monarchE

Das ist eine Veranstaltung von


The new approval of abemaciclib in the adjuvant setting* opens up further treatment options for patients with HR+, HER2- early breast cancer (EBC) and a high risk of recurrence#.

What difference will this make in practice?

We invite you to participate in our virtual Lilly event with Prof. P. Fasching (GER) , Prof. W. Janni (GER) and Prof. S. Johnston (UK) and learn more about the new clinically relevant data on the treatment of HR+, HER2- EBC* and its implications for everyday clinical practice.


Prof. Dr. Peter A. Fasching
Oberarzt an der Frauenklinik des Universitätsklinikums Erlangen


Prof. Dr. Wolfgang Janni
Direktor der Frauenklinik am Universitätsklinikum Ulm​


Prof. Dr. Stephen Johnston
The Royal Marden NHS Foundation Trust & Institute of Cancer Research Chelsea, London, UK


23.06.2022, 18:00 – 19:00 Uhr


Das ist eine Veranstaltung von